I am a board-certified hematologist who specializes in the treatment of acute myeloid leukemia (AML) and other myeloid malignancies. Our knowledge of AML in recent years has skyrocketed; with targeted treatments driven by molecular diagnostics available for some patients. While targeted therapies have increased options for patients, it has also resulted in increasingly complex decision making. In the clinic, I attempt to draw on our wealth of AML patient experience to optimize decisions regarding chemotherapy, targeted therapy, immunotherapy and transplantation. In the lab, I am developing cellular immunotherapies, such as chimeric antigen receptor (CAR) T-cell therapy, for patients with AML.